Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

TMB-365

Phase 2Small molecule

TTaiMed Biologics Inc.

TMB-365 is one of 56 small molecule programs targeting HIV-1 infection. It is currently in Phase 2.

1

Indications

2

Total Trials

1

Active Trials

55

Competitors

Pipeline

Status by Indication[3][1]

Indication

HIV-1 InfectionActive, not recruiting

HIV-1 InfectionPhase 2

Active, not recruiting

Competition

Competitive Landscape

61 competitors in HIV-1 Infection

#DrugCompanyPhaseTrials

Cabenuva

Epidiolex

Jazz Pharmaceuticals

Tybost

Niacor

Taxol

Vemlidy

Emtriva

Istodax

Renvela

Ziagen

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

HIV-1 Infection

NCT07215468

Clinical

Trials by Indication[1]

HIV-11 trial

Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants

Completed·TTaiMed Biologics Inc.·Phase 1·NCT04027387·24 enrolled

HIV-1 infection1 trial

A Phase 2b Study of the Safety, Pharmacokinetics, and Efficacy of the Combination of TMB-365 and TMB-380 as Maintenance Therapy in HIV-1 Infected Individuals Suppressed With Combination Antiretroviral Therapy

Active, not recruiting·TTaiMed Biologics Inc.·Phase 2·NCT07215468·88 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for TMB-365. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TMB-365 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TMB-365. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — TaiMed Biologics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTaiMed Biologics Inc.

Related News